Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer

Surgery (United States)

Volumn 156, Issue 1, 2014, Pages 97-108

  Bronsert, Peter ^a,b   Kohler, Ilona ^a   Timme, Sylvia ^a   Kiefer, Selina ^a   Werner, Martin ^a,b,c   Schilling, Oliver ^b   Vashist, Yogesh ^d   Makowiec, Frank ^a,b   Brabletz, Thomas ^a,c   Hopt, Ulrich T ^a   Bausch, Dirk ^a,e   Kulemann, Birte ^a   Keck, Tobias ^a,e   Wellner, Ulrich F ^a,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e Clinic for Surgery   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; PAN CYTOKERATIN; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FIBROBLAST; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; FIBROBLASTS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84902479218     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2014.02.018     Document Type: Article

References (46)

1. S.R. Bramhall, W.H. Allum, A.G. Jones, A. Allwood, C. Cummins, and J.P. Neoptolemos Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study Br J Surg 82 1995 111 115
2. M. Carpelan-Holmstrom, S. Nordling, E. Pukkala, R. Sankila, J. Luttges, and G. Kloppel et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry Gut 54 2005 385 387
3. J. He, N. Ahuja, M.A. Makary, J.L. Cameron, F.E. Eckhauser, and M.A. Choti et al. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades HPB (Oxford) 16 2014 83 90
4. J.M. Winter, M.F. Brennan, L.H. Tang, M.I. D'Angelica, R.P. Dematteo, and Y. Fong et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades Ann Surg Oncol 19 2012 169 175
5. U. Wellner, J. Schubert, U.C. Burk, O. Schmalhofer, F. Zhu, and A. Sonntag et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs Nat Cell Biol 11 2009 1487 1495
6. T. Brabletz To differentiate or not - routes towards metastasis Nat Rev Cancer 12 2012 425 436
7. C.L. Chaffer, N.D. Marjanovic, T. Lee, G. Bell, C.G. Kleer, and F. Reinhardt et al. Poised Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity Cell 154 2013 61 74
8. C.P. Bracken, P.A. Gregory, N. Kolesnikoff, A.G. Bert, J. Wang, and M.F. Shannon et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition Cancer Res 68 2008 7846 7854
9. U. Burk, J. Schubert, U. Wellner, O. Schmalhofer, E. Vincan, and S. Spaderna et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells EMBO Rep 9 2008 582 589
10. R. Kalluri, and M. Zeisberg Fibroblasts in cancer Nat Rev Cancer 6 2006 392 401
11. M. Erkan, G. Adler, M.V. Apte, M.G. Bachem, M. Buchholz, and S. Detlefsen et al. StellaTUM: current consensus and discussion on pancreatic stellate cell research Gut 61 2012 172 178
12. M. Erkan, S. Hausmann, C.W. Michalski, A.A. Fingerle, M. Dobritz, and J. Kleeff et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications Nat Rev Gastroenterol Hepatol 9 2012 454 467
13. F.T. Bosman, F. Carneiro, R.H. Hruban, and N.D. Theise WHO classification of tumors of the digestive system 4th ed. 2010 International Agency for Research in Cancer Lyon
14. S. Hamilton, and L. Aaltonen Pathology and genetics and pathology of tumors of the digestive system 1st ed. 2000 International Agency for Research in Cancer Lyon
15. A. Broders Squamous-cell epithelioma of the lip: a study of five hundred and thirty-seven cases JAMA 74 1920 656 664
16. J.R. Wright Jr., and C. Albert Broders' paradigm shifts involving the prognostication and definition of cancer Arch Pathol Lab Med 136 2012 1437 1446
17. B.J. John, P. Naik, A. Ironside, B.R. Davidson, G. Fusai, and R. Gillmore et al. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival HPB (Oxford) 15 2013 674 680
18. F. Petrelli, K. Borgonovo, and S. Barni The emerging issue of ratio of metastatic to resected lymph nodes in gastrointestinal cancers: an overview of literature Eur J Surg Oncol 37 2011 836 847
19. E. Pomianowska, A. Westgaard, Ø. Mathisen, O.P.F. Clausen, and I.P. Gladhaug Prognostic relevance of number and ratio of metastatic lymph nodes in resected pancreatic, ampullary, and distal bile duct carcinomas Ann Surg Oncol 20 2013 233 241
20. N.P. Valsangkar, D.M. Bush, J.S. Michaelson, C.R. Ferrone, J.A. Wargo, and K.D. Lillemoe et al. N0/N1, PNL, or LNR? The effect of lymph node number on accurate survival prediction in pancreatic ductal adenocarcinoma J Gastrointest Surg 17 2013 257 266
21. K. Aigner, B. Dampier, L. Descovich, M. Mikula, A. Sultan, and M. Schreiber et al. The transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity Oncogene 26 2007 6979 6988
22. J.E. Remacle, H. Kraft, W. Lerchner, G. Wuytens, C. Collart, and K. Verschueren et al. New mode of DNA binding of multi-zinc finger transcription factors: deltaEF1 family members bind with two hands to two target sites EMBO J 18 1999 5073 5084
23. J.P. Thiery, H. Acloque, R.Y. Huang, and M.A. Nieto Epithelial- mesenchymal transitions in development and disease Cell 139 2009 871 890
24. T.T. Onder, P.B. Gupta, S.A. Mani, J. Yang, E.S. Lander, and R.A. Weinberg Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways Cancer Res 68 2008 3645 3654
25. G. Lahat, Q.S. Zhu, K.L. Huang, S. Wang, S. Bolshakov, and J. Liu et al. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies PloS One 5 2010 e10105
26. S.A. Mani, W. Guo, M.J. Liao, E.N. Eaton, A. Ayyanan, and A.Y. Zhou et al. The epithelial-mesenchymal transition generates cells with properties of stem cells Cell 133 2008 704 715
27. T. Arumugam, V. Ramachandran, K.F. Fournier, H. Wang, L. Marquis, and J.L. Abbruzzese et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer Cancer Res 69 2009 5820 5828
28. J. Schulte, M. Weidig, P. Balzer, P. Richter, M. Franz, and K. Junker et al. Expression of the E-cadherin repressors Snail, Slug and Zeb1 in urothelial carcinoma of the urinary bladder: relation to stromal fibroblast activation and invasive behaviour of carcinoma cells Histochem Cell Biol 138 2012 847 860
29. M. Singh, N.S. Spoelstra, A. Jean, E. Howe, K.C. Torkko, and H.R. Clark et al. ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease Mod Pathol 21 2008 912 923
30. S. Spaderna, O. Schmalhofer, F. Hlubek, G. Berx, A. Eger, and S. Merkel et al. A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer Gastroenterology 131 2006 830 840
31. M.F. Clarke, J.E. Dick, P.B. Dirks, C.J. Eaves, C.H. Jamieson, and D.L. Jones et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells Cancer Res 66 2006 9339 9344
32. C. Feig, A. Gopinathan, A. Neesse, D.S. Chan, N. Cook, and D.A. Tuveson The pancreas cancer microenvironment Clin Cancer Res 18 2012 4266 4276
33. P. Cirri, and P. Chiarugi Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression Cancer Metastasis Rev 31 2012 195 208
34. S. Goruppi, and G.P. Dotto Mesenchymal stroma: primary determinant and therapeutic target for epithelial cancer Trends Cell Biol 23 2013 593 602
35. M. Erkan, C.W. Michalski, S. Rieder, C. Reiser-Erkan, I. Abiatari, and A. Kolb et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma Clin Gastroenterol Hepatol 6 2008 1155 1161
36. X.-B. Cheng, N. Sato, S. Kohi, and K. Yamaguchi Prognostic impact of hyaluronan and its regulators in pancreatic ductal adenocarcinoma PLoS One 8 2013 e80765
37. P. Mahawithitwong, K. Ohuchida, N. Ikenaga, H. Fujita, M. Zhao, and S. Kozono et al. Kindlin-2 expression in peritumoral stroma is associated with poor prognosis in pancreatic ductal adenocarcinoma Pancreas 42 2013 663 669
38. S. Yuzawa, M.R. Kano, T. Einama, and H. Nishihara PDGFRβ expression in tumor stroma of pancreatic adenocarcinoma as a reliable prognostic marker Med Oncol 29 2012 2824 2830
39. D. Ohlund, C. Lundin, B. Ardnor, M. Oman, P. Naredi, and M. Sund Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer Br J Cancer 101 2009 91 97
40. J.R. Infante, H. Matsubayashi, N. Sato, J. Tonascia, A.P. Klein, and T.A. Riall et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma J Clin Oncol 25 2007 319 325
41. K. Tobita, H. Kijima, S. Dowaki, Y. Oida, H. Kashiwagi, and M. Ishii et al. Thrombospondin-1 expression as a prognostic predictor of pancreatic ductal carcinoma Int J Oncol 21 2002 1189 1195
42. B. Orr, A.C.P. Riddick, G.D. Stewart, R.A. Anderson, O.E. Franco, and S.W. Hayward et al. Identification of stromally expressed molecules in the prostate by tag-profiling of cancer-associated fibroblasts, normal fibroblasts and fetal prostate Oncogene 31 2012 1130 1142
43. Y. Liu, S. El-Naggar, D.S. Darling, Y. Higashi, and D.C. Dean Zeb1 links epithelial-mesenchymal transition and cellular senescence Development 135 2008 579 588
44. Y.-C. Chang, C.-H. Tsai, Y.-L. Lai, C.-C. Yu, W.-Y. Chi, and J.J. Li et al. Arecoline-induced myofibroblast transdifferentiation from human buccal mucosal fibroblasts is mediated by ZEB1 J Cell Mol Med 2014 Jan 8 [epub ahead of print]
45. I. Esposito, J. Kleeff, F. Bergmann, C. Reiser, E. Herpel, and H. Friess et al. Most pancreatic cancer resections are R1 resections Ann Surg Oncol 15 2008 1651 1660
46. K.V. Menon, D. Gomez, A.M. Smith, A. Anthoney, and C.S. Verbeke Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP) HPB (Oxford) 11 2009 18 24